Condensate Therapeutics for Cardiovascular Diseases

CD BioSciences is dedicated to developing disease-targeted condensate therapeutics to advance the field of refractory diseases. Here, we offer condensate therapeutics for cardiovascular diseases, offering new hope for the treatment of cardiomyopathy and atherosclerosis.

Condensate Research Offers New Hope for the Treatment of Cardiovascular Diseases

Cardiovascular disease (CVD) encompasses a group of heart and vascular diseases ranging from peripheral arteries, coronary arteries, heart valves, myocardium, and congenital heart disease to cardiac arrhythmias that ultimately lead to heart failure. Despite recent advances in clinical treatment, CVD remains the leading cause of death worldwide. Therefore, it is important to gain insight into the molecular mechanisms of CVD. Studies have shown that many phase-separated biomolecular condensates are closely associated with CVD. For example, lncRNA can influence the progression of CVD. Misfolded proteins may accumulate in cells due to mutations and cause dilated cardiomyopathy. In addition, stress granules can form in diseases such as hypertrophic cardiomyopathy and atrial fibrillation. The study of biomolecular condensates to prevent or treat CVD offers new solutions.

Fig. 1. Possible ways through which drugs affect phase separation. (Mo Y, et al, 2022)

Our Solutions

CD BioSciences offers comprehensive services to analyze abnormally altered biomolecular condensates in CVD with the goal of developing therapeutic targets. CD BioSciences is also actively engaged in strategic partnerships with pharmaceutical companies, regulatory agencies, and healthcare providers working to develop condensate therapeutics targeting cardiovascular disease. These collaborations allow us to accelerate the translation of condensate therapeutics into clinical trials and ultimately provide innovative treatment options for CVD patients.

Through advanced omics techniques and computational models, we can help you unravel the complex interplay between phase-separated, genetic variation and environmental factors in the context of CVD. Our solutions help personalize therapies and can optimize treatment outcomes and minimize adverse effects.

Leveraging our expertise in coagulation and drug development, our experts harness the power of condensates to deliver novel and effective therapeutic strategies for CVD:

• Developing Small Molecules Drugs
  We design and develop short peptides to competitively bind key sites or proteins involved in the condensate assembly process, thereby inhibiting phase separation. By disrupting the formation of disease-associated condensates, we aim to mitigate the pathological effects of aberrant phase separation in CVD.
• Modulating Condensate Stability
  Another aspect of our condensate treatment approach involves modulating the external environment of the condensate to achieve stable phase separation. This can be achieved by adjusting factors such as pH, salt concentration, or introducing specific drugs that affect the behavior of the condensate. By fine-tuning the nature of the condensate, we have the potential to restore cellular homeostasis and mitigate the disease manifestations of CVD.

CD BioSciences is committed to pioneering condensate therapeutics for cardiovascular disease. Our goal is to harness the potential of condensates to revolutionize the treatment of CVD. By developing innovative strategies to inhibit phase separation and modulate condensate stability, we believe condensate therapeutics will provide personalized and targeted interventions for CVD patients. If you are interested in our solutions, please contact us for more information.